Welcome to our dedicated page for HTBX news (Ticker: HTBX), a resource for investors and traders seeking the latest updates and insights on HTBX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HTBX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HTBX's position in the market.
NightHawk Biosciences (NHWK) reported first-quarter updates for 2022, highlighting significant advancements in its transformation to a fully integrated biopharmaceutical company. Key developments include the acquisition of Elusys Therapeutics, enhancing its biodefense offerings with ANTHIM®, and securing an international contract with Canada. Financially, grant revenue decreased to $0.2 million, while R&D expenses rose to $3.9 million. The company reported an $8.1 million net loss and has $84.1 million in cash reserves as of March 31, 2022.
On May 10, 2022, NightHawk Biosciences (NYSE American: NHWK) announced that Dr. Matthew Seavey will present data on PTX-35 at the 4th Annual Treg Directed Therapies Summit from May 17-19 in Boston. PTX-35 is a novel antibody immunomodulator targeting TNFRSF25, currently undergoing Phase 1 trials for solid tumors. The presentation will cover Treg expansion for treating human diseases. The event highlights include showcasing preclinical efficacy and exploring new indications and partnerships for Treg therapies.
Nighthawk Biosciences, previously Heat Biologics, has officially changed its name and ticker symbol to NHWK on May 3, 2022. This rebranding reflects the company's transition to a fully integrated biopharmaceutical firm focused on drug development. Nighthawk aims to streamline the drug discovery process through its ecosystem of subsidiaries, enhancing capabilities in manufacturing and biodefense. CEO Jeff Wolf emphasized that the name change aligns with their strategy to efficiently move drugs from discovery to commercialization, without impacting shareholder rights or share structure.
Heat Biologics (HTBX), to be renamed NightHawk Biosciences, announced a CAD $7.9 million contract with the Canadian government for the supply of ANTHIM®, a treatment for inhalation anthrax, marking the company’s first international sale. This agreement, following the acquisition of Elusys Therapeutics, aims to enhance Canada’s emergency preparedness against potential anthrax biothreats. Notably, Elusys has secured over $400 million in contracts from U.S. agencies, which supports its credibility in biodefense.
Heat Biologics, Inc. (HTBX), soon to be renamed NightHawk Biosciences, has completed its acquisition of Elusys Therapeutics, Inc., a biodefense company known for ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. The acquisition enhances NightHawk's biodefense capabilities and includes plans to move ANTHIM® manufacturing to a new facility in Kansas. Elusys has secured over $350 million in funding from government bodies like BARDA. The strategic acquisition aims to leverage existing distribution channels and expand ANTHIM®'s international reach.
Heat Biologics, Inc. will transition to NightHawk Biosciences, effective May 3, 2022, reflecting its evolving focus on biodefense and enhanced drug development capabilities. The ticker symbol will change to NHWK. Key updates include progress in clinical trials and partnerships, notably with Kansas State University, and an expansion in biodefense efforts. The company emphasizes a fully-integrated ecosystem for rapid, efficient drug delivery. CEO Jeff Wolf discusses overcoming barriers in drug development through this integration.
DURHAM, N.C., April 18, 2022 – Heat Biologics (NYSE American: HTBX) is hosting a livestream event on April 19, 2022, at 10:30 AM ET to discuss recent developments. Investors can join the event at this link. Heat Biologics focuses on developing innovative therapies and vaccines to modulate the immune system, featuring its gp96 platform. Ongoing projects include HS-110 in Phase 2 trials, and other immunomodulatory products in various development stages. For additional details, visit www.heatbio.com.
Heat Biologics (NYSE American: HTBX) announced plans for a new 500,000+ square foot biomanufacturing facility in Manhattan, Kansas. In partnership with the State of Kansas and local affiliates, this facility aims to focus on large molecule and biologics manufacturing, particularly for biodefense. Expected to employ over 500 individuals, it will also serve as a Contract Development and Manufacturing Organization. The facility is projected to have a billion-dollar economic impact in Kansas, responding to a growing biologics market expected to reach $567 billion by 2028.
DURHAM, N.C., April 14, 2022 – Heat Biologics (NYSE American: HTBX) will host an investor and media livestream event on April 19, 2022, at 10:30 AM ET to discuss recent developments. The company focuses on first-in-class therapies to modulate the immune system, leveraging its gp96 platform for various product candidates. Notable developments include the completion of enrollment in a Phase 2 trial for HS-110 and ongoing Phase 1 trials for PTX-35 and HS-130.
Heat Biologics (NYSE American: HTBX) announced a new 3-D cell therapy manufacturing process aimed at enhancing yield and operational efficiency for its HS-110 therapy and other cellular products. CEO Jeff Wolf highlighted the transition from 2-D to 3-D processes, which are expected to support Phase 3 trials and commercialization while providing services to other biopharma firms. The company plans to discuss these improvements with the FDA in an upcoming Type C meeting and is optimistic about accelerating partnerships post-FDA interaction.
FAQ
What is the market cap of HTBX (HTBX)?
